Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

Key Points

• CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $35.11, generating approximately $7.02 million. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan and reduced his holdings by 12.51% to 1.4 million shares.
• Venker has made three other 200,000-share sales since July, totaling more than $21.4 million, while institutional investors hold approximately 64.76% of Roivant’s stock.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $45.64 price target. Roivant recently beat quarterly EPS estimates, although it reported minimal revenue and continues to post significant losses.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $35.11, for a total value of $7,022,000.00. Following the transaction, the chief executive officer owned 1,399,154 shares in the company, valued at approximately $49,124,296.94. This represents a 12.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.77, for a total transaction of $7,154,000.00.
• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.95, for a total transaction of $6,990,000.00.

Roivant Sciences Stock Performance

ROIV traded up $0.65 on Thursday, hitting $37.45. The company had a trading volume of 13,451,164 shares, compared to its average volume of 6,449,771. The stock has a market capitalization of $27.05 billion, a price-to-earnings ratio of -70.66 and a beta of 1.10. The stock has a fifty day moving average price of $36.59 and a 200-day moving average price of $33.26. Roivant Sciences Ltd. has a 12-month low of $17.89 and a 12-month high of $42.50.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. Analysts forecast that Roivant Sciences Ltd. will post -2.00 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Guggenheim raised their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. HC Wainwright boosted their price target on Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research note on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Finally, Jefferies Financial Group boosted their price objective on Roivant Sciences from $42.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $45.64.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Waverly Advisors LLC raised its position in Roivant Sciences by 2.3% in the second quarter. Waverly Advisors LLC now owns 12,869 shares of the company's stock valued at $455,000 after purchasing an additional 291 shares during the period. Fifth Third Bancorp increased its stake in Roivant Sciences by 8.7% during the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock worth $130,000 after buying an additional 376 shares during the period. Bessemer Group Inc. increased its position in shares of Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after acquiring an additional 441 shares during the period. Fifth Third Wealth Advisors LLC raised its position in Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock valued at $282,000 after purchasing an additional 445 shares in the last quarter. Finally, Versant Capital Management Inc lifted its stake in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock worth $141,000 after acquiring an additional 487 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Successful Phase 3 trials: Brepocitinib met the primary endpoint in both the CLARITY-1 and CLARITY-2 studies. It also delivered statistically significant and clinically meaningful improvements across key secondary measures, including sustained steroid-free disease control at Week 48, reduced chorioretinal vascular leakage, resolution of macular edema and improved patient-reported visual functioning. Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials
• Positive Sentiment: Commercial opportunity expanded: The trial outcomes may enable Roivant and Priovant to seek a label expansion for Lisraya in uveitis, potentially broadening the product’s addressable market. The benefits were reported despite an aggressive steroid taper, which may make the data more compelling for physicians seeking to reduce steroid exposure. Roivant to Seek Label Expansion for Lisraya in Uveitis
• Positive Sentiment: Investor reaction: Multiple market reports characterized the stock’s move as a response to the positive uveitis data, indicating that investors viewed the results as an important clinical and pipeline catalyst. Roivant Sciences Says Brepocitinib Meets Primary Goal in Uveitis Trials
• Neutral Sentiment: Upcoming financial update: Roivant will report results for the quarter ended September 30, 2026, and provide a business update on November 9. The call could offer additional information on regulatory plans, commercialization timing and the broader pipeline. Roivant to Report Second-Quarter Financial Results

Roivant Sciences Company Profile

Roivant Sciences Ltd. NASDAQ: ROIV is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.